PBS0 Stock Overview
An advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Precision BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.35 |
| 52 Week High | US$17.44 |
| 52 Week Low | US$6.35 |
| Beta | 1.69 |
| 11 Month Change | -20.63% |
| 3 Month Change | -24.85% |
| 1 Year Change | -44.59% |
| 33 Year Change | -97.48% |
| 5 Year Change | -98.71% |
| Change since IPO | -98.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBS0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -14.2% | 0.8% | -1.3% |
| 1Y | -44.6% | -17.5% | 7.4% |
Return vs Industry: PBS0 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: PBS0 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| PBS0 volatility | |
|---|---|
| PBS0 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PBS0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PBS0's weekly volatility has decreased from 15% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 108 | Michael Amoroso | www.precisionbiosciences.com |
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Precision BioSciences, Inc. Fundamentals Summary
| PBS0 fundamental statistics | |
|---|---|
| Market cap | €49.55m |
| Earnings (TTM) | €10.95m |
| Revenue (TTM) | €71.64m |
4.1x
P/E Ratio0.6x
P/S RatioIs PBS0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBS0 income statement (TTM) | |
|---|---|
| Revenue | US$75.10m |
| Cost of Revenue | US$0 |
| Gross Profit | US$75.10m |
| Other Expenses | US$63.62m |
| Earnings | US$11.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.59 |
| Gross Margin | 100.00% |
| Net Profit Margin | 15.28% |
| Debt/Equity Ratio | 34.3% |
How did PBS0 perform over the long term?
See historical performance and comparison